Cargando…
Influencing factors on the NMP-22 urine assay: an experimental model
BACKGROUND: The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor antigen or some other phenomenon associated with the disease state. In this study, we...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480828/ https://www.ncbi.nlm.nih.gov/pubmed/22928931 http://dx.doi.org/10.1186/1471-2490-12-23 |
_version_ | 1782247632529260544 |
---|---|
author | Miyake, Makito Goodison, Steve Giacoia, Evan Gomes Rizwani, Wasia Ross, Shanti Rosser, Charles J |
author_facet | Miyake, Makito Goodison, Steve Giacoia, Evan Gomes Rizwani, Wasia Ross, Shanti Rosser, Charles J |
author_sort | Miyake, Makito |
collection | PubMed |
description | BACKGROUND: The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor antigen or some other phenomenon associated with the disease state. In this study, we investigated the influence of urinary cellular and protein concentration, and hematuria on the performance of the NMP-22 tests in an experimental model. METHODS: Pooled urine from healthy subjects were spiked with varying concentrations of benign (UROtsa) cells, cancer cells (RT4, T24, KU-7 and UM-UC-14), whole blood or serum, prior to analysis with both NMP22® Bladder Cancer ELISA test and the NMP22® BladderChek® point-of-care test. RESULTS: Urines from control subjects were negative for NMP-22. The addition of whole blood at 50ul/10 ml, but not serum, resulted in a false-positive result. Furthermore, the addition of a high concentration of benign urothelial cells (10(6)) or the cell lysate from these cells (306 μg protein) resulted in a false-positive result. High concentrations of pooled-cancer cells (10(6)) or cell lysate (30.6 μg and above) resulted in a positive NMP-22 assay. Concordance between the NMP-22 ELISA assay and the NMP-22 point of care assay was >90%. CONCLUSIONS: Rather than detecting a specific tumor antigen, urinary NMP-22 assays may be measuring the cellularity or amount of cell turnover that may be introduced into the urine by a variety of conditions, including surface shedding from bladder tumors. The absence of significant urinary cellularity in some cases due to lesion characteristics or the timing of sampling may result in false-negative NMP-2 assays. |
format | Online Article Text |
id | pubmed-3480828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34808282012-10-27 Influencing factors on the NMP-22 urine assay: an experimental model Miyake, Makito Goodison, Steve Giacoia, Evan Gomes Rizwani, Wasia Ross, Shanti Rosser, Charles J BMC Urol Research Article BACKGROUND: The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor antigen or some other phenomenon associated with the disease state. In this study, we investigated the influence of urinary cellular and protein concentration, and hematuria on the performance of the NMP-22 tests in an experimental model. METHODS: Pooled urine from healthy subjects were spiked with varying concentrations of benign (UROtsa) cells, cancer cells (RT4, T24, KU-7 and UM-UC-14), whole blood or serum, prior to analysis with both NMP22® Bladder Cancer ELISA test and the NMP22® BladderChek® point-of-care test. RESULTS: Urines from control subjects were negative for NMP-22. The addition of whole blood at 50ul/10 ml, but not serum, resulted in a false-positive result. Furthermore, the addition of a high concentration of benign urothelial cells (10(6)) or the cell lysate from these cells (306 μg protein) resulted in a false-positive result. High concentrations of pooled-cancer cells (10(6)) or cell lysate (30.6 μg and above) resulted in a positive NMP-22 assay. Concordance between the NMP-22 ELISA assay and the NMP-22 point of care assay was >90%. CONCLUSIONS: Rather than detecting a specific tumor antigen, urinary NMP-22 assays may be measuring the cellularity or amount of cell turnover that may be introduced into the urine by a variety of conditions, including surface shedding from bladder tumors. The absence of significant urinary cellularity in some cases due to lesion characteristics or the timing of sampling may result in false-negative NMP-2 assays. BioMed Central 2012-08-28 /pmc/articles/PMC3480828/ /pubmed/22928931 http://dx.doi.org/10.1186/1471-2490-12-23 Text en Copyright ©2012 Miyake et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Miyake, Makito Goodison, Steve Giacoia, Evan Gomes Rizwani, Wasia Ross, Shanti Rosser, Charles J Influencing factors on the NMP-22 urine assay: an experimental model |
title | Influencing factors on the NMP-22 urine assay: an experimental model |
title_full | Influencing factors on the NMP-22 urine assay: an experimental model |
title_fullStr | Influencing factors on the NMP-22 urine assay: an experimental model |
title_full_unstemmed | Influencing factors on the NMP-22 urine assay: an experimental model |
title_short | Influencing factors on the NMP-22 urine assay: an experimental model |
title_sort | influencing factors on the nmp-22 urine assay: an experimental model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480828/ https://www.ncbi.nlm.nih.gov/pubmed/22928931 http://dx.doi.org/10.1186/1471-2490-12-23 |
work_keys_str_mv | AT miyakemakito influencingfactorsonthenmp22urineassayanexperimentalmodel AT goodisonsteve influencingfactorsonthenmp22urineassayanexperimentalmodel AT giacoiaevangomes influencingfactorsonthenmp22urineassayanexperimentalmodel AT rizwaniwasia influencingfactorsonthenmp22urineassayanexperimentalmodel AT rossshanti influencingfactorsonthenmp22urineassayanexperimentalmodel AT rossercharlesj influencingfactorsonthenmp22urineassayanexperimentalmodel |